Comparative Pharmacology
Head-to-head clinical analysis: ZEBETA versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZEBETA versus ZIAC.
ZEBETA vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker). Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
Initial dose 5 mg orally twice daily; may increase to 10 mg twice daily after 2 weeks; maximum 20 mg twice daily.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function, allowing once-daily dosing.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Approximately 50% of an oral dose is excreted unchanged in urine; the remainder is hepatically metabolized with biliary excretion of metabolites contributing to fecal elimination.
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker
Beta Blocker + Diuretic